sorry, we can't preview this file

DataSheet_1_A Longitudinal Study of Immune Cells in Severe COVID-19 Patients.docx (953.89 kB)

DataSheet_1_A Longitudinal Study of Immune Cells in Severe COVID-19 Patients.docx

Download (953.89 kB)
posted on 23.10.2020, 05:29 by Didier Payen, Maxime Cravat, Hadil Maadadi, Carole Didelot, Lydia Prosic, Claire Dupuis, Marie-Reine Losser, Marcelo De Carvalho Bittencourt

Little is known about the time-dependent immune responses in severe COVID-19. Data of 15 consecutive patients were sequentially recorded from intensive care unit admission. Lymphocyte subsets and total monocyte and subsets counts were monitored as well as the expression of HLA-DR. For 5 patients, SARS-CoV-2–specific T-cell polyfunctionality was assessed against Spike and Nucleoprotein SARS-CoV-2 peptides. Non-specific inflammation markers were increased in all patients. Median monocyte HLA-DR expression was below the 8,000 AB/C threshold defining acquired immunodepression. A “V” trend curve for lymphopenia, monocyte numbers, and HLA-DR expression was observed with a nadir between days 11 and 14 after symptoms’ onset. Intermediate CD14++CD16+ monocytes increased early with a reduction in classic CD14++CD16- monocytes. Polyfunctional SARS-Cov-2–specific CD4 T-cells were present and functional, whereas virus-specific CD8 T-cells were less frequent and not efficient. We report a temporal variation of both innate and adaptive immunity in severe COVID-19 patients, helpful in guiding therapeutic decisions (e.g. anti-inflammatory vs. immunostimulatory ones). We describe a defect in virus-specific CD8 T-cells, a potential biomarker of clinical severity. These combined data also provide helpful knowledge for vaccine design.

Clinical Trial Registration, identifier NCT04386395